The Medicines Company (NASDAQ:MDCO) : $6.12 million worth of transactions were on upticks in The Medicines Company (NASDAQ:MDCO), compared to $5.36 million on downticks. The ratio between the two was 1.14, whereas, the net money flow stood at a healthy $0.77 million on Wednesdays session.The block trades show a bullish bias with only $1.65 million worth of transactions done on downticks. The consistent buying on upticks in the stock accounted for $2.37million worth of trades. The up-down ratio between the uptick and downtick was 1.44, confirming that the stronger hands have been buying the stock on every weakness. The total money flow into the stock stood at $0.73 million. The bulls and the bears were in an equilibrium as the stock closed with a loss of -2.57%. The stock was trading at $33.8, with a drop of $0.89 over the previous days close. The stock recorded 1.62% for the week.
In an insider trading activity, According to the information disclosed by the Securities and Exchange Commission in a Form 4 filing, the officer (EVP & Chief Corp. Dev. Officer) of Medicines Co /De, Cox Christopher T, had purchased 45,985 shares in a transaction dated on June 8, 2016. The transaction was executed at $37.62 per share with total amount equaling $1,729,956. Currently the company Insiders own 7.9% of The Medicines Company shares according to the proxy statements. During last six month period, the net percent change held by insiders has seen a change of -30.41%.
The company shares have rallied 22.41% from its 1 Year high price. On Sep 17, 2015, the shares registered one year high at $43.79 and the one year low was seen on Jul 2, 2015. The 50-Day Moving Average price is $35.96 and the 200 Day Moving Average price is recorded at $34.34. The Medicines Company (NASDAQ:MDCO): The stock opened at $35.00 on Wednesday but the bulls could not build on the opening and the stock topped out at $35.09 for the day. The stock traded down to $33.72 during the day, due to lack of any buying support eventually closed down at $33.80 with a loss of -2.57% for the day. The stock had closed at $34.69 on the previous day. The total traded volume was 842,634 shares.
The Medicines Company is a global biopharmaceutical company. The Companys marketed products are: Angiomax (bivalirudin), Cleviprex (clevidipine) injectable emulsion, Minocin (minocycline) for injection, Orbactiv (oritavancin), PreveLeak and Recothrom Thrombin topical (Recombinant). The Companys products in development include its registration stage product candidates and its research and development product candidates. It has a pipeline of acute and intensive care hospital products in development, including four registration stage product candidates for which the Company has submitted applications for regulatory approval in the United States, cangrelor, IONSYS (fentanyl iontophoretic transdermal system), Raplixa, formerly referred to as Fibrocaps, and RPX-602. The Companys four research and development product candidates include ABP-700, ALN-PCSsc, Carbavance and MDCO-216. The Company also develops ABP-700, an intravenous anesthetic, which is in Phase I of clinical studies.